Livmoniplimab (ABBV-151, ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFbeta1, which blocks TGFbeta1 release mediated by LRRC32, for the treatment of locally advanced or metastatic solid tumours.
Purity:
95%
CAS Number:
[2412004-88-5]
Target:
TGF-beta/Smad
* VAT and and shipping costs not included. Errors and price changes excepted